74849
document
[ Supplementary treatment with Esberitox of female patients undergoing curative adjuvant irradiation following breast cancer ] . 1 . The study was supposed to investigate a possible prevention or reduction of the toxicity of radiotherapy by an additional treatment with Esberitox . This question arose when performing an investigation about the effect of Esberitox in a combined chemo-radiotherapy . Whereas the latter induces above all a systemic damage to the hemopoietic system , radiotherapy is a regional noxa . 2 . The present prospective , randomized study was conducted with 50 patients submitted to curative adjuvant irradiation following surgery for mammary carcinoma . The radiotherapy was performed in the same way in all patients with irradiations of the thoracic wall and the regional lymph nodes . Two groups were built by randomization . The study group received an additional treatment with Esberitox , the control group did not receive an additional treatment . 3 . As a result , no protective influence of Esberitox could be demonstrated . The parameters investigated were the peripheral blood count ( leucocytes , granulocytes , lymphocytes , monocytes , thrombocytes , hemoglobin , hematocrit ) and the incidence of infections . 4 . This result diverging from literature is discussed . It is probably affected by volume and extension of the injury induced by a hematotoxic noxa and furthermore by the ability of regeneration . If this ability is exhausted , the protective effect of Esberitox can act no longer . Therefore the essential factor seems to be the duration of exposure to the noxa . Esberitox was effective in case of a short toxicity , it was ineffective in case of prolonged toxicity , if the treatment continuity ( noxa ) was not broken up by some regeneration intervals . The radiotherapy studied in this trial had a duration of 50 days , and its effect was that of a longterm injury .
74850
Intervention_Pharmacological
Esberitox
74851
Intervention_Pharmacological
curative adjuvant irradiation
74852
Intervention_Pharmacological
radiotherapy
74853
Intervention_Pharmacological
Esberitox .
74854
Intervention_Pharmacological
Esberitox
74855
Intervention_Pharmacological
curative adjuvant irradiation
74856
Intervention_Pharmacological
radiotherapy
74857
Intervention_Pharmacological
Esberitox
74858
Intervention_Control
control group did not receive an additional treatment .
74859
Intervention_Pharmacological
radiotherapy
74860
Outcome_Physical
prevention or reduction of the toxicity
74861
Outcome_Physical
peripheral blood count ( leucocytes , granulocytes , lymphocytes , monocytes , thrombocytes , hemoglobin , hematocrit ) and the incidence of infections
74862
Participant_Condition
female patients undergoing curative adjuvant irradiation following breast cancer ]